Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation

Hepatology

Volumn 53, Issue 1, 2011, Pages 160-170

  Lee, Terence Kin Wah ^a,b   Castilho, Antonia ^a,b   Cheung, Vincent Chi Ho ^a,b   Tang, Kwan Ho ^b   Ma, Stephanie ^a,b   Ng, Irene Oi Lin ^a,b  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CISPLATIN; DOXORUBICIN; LENTIVIRUS VECTOR; LUPEOL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL RENEWAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER TUMOR; LIVER TUMOR INITIATING CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; GLYCOPROTEINS; HUMANS; LIVER NEOPLASMS; MICE; NEOPLASM TRANSPLANTATION; PENTACYCLIC TRITERPENES; PEPTIDES; PTEN PHOSPHOHYDROLASE;

EID: 78751552761     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24000     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu Y, Murray T, et al. Cancer statistics. CA Cancer J Clin 2008; 58: 71-96.
2. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004; 127: 218-224.
3. Kassahun WT, Fangmann J, Harm J, Hauss J, Bartels M. Liver resection and transplantation in the management of hepatocellular carcinoma: a review. Ex Clin Transplant 2006; 4: 549-558.
4. Aguayo A, Patt YZ. Nonsurgical treatment of hepatocellular carcinoma. Semin Oncol 2001; 28: 503-513.
5. Kuvshinoff BW, Ota DM. Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery 2002; 132: 605-611.
6. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. HEPATOLOGY 2003; 37: 429-442.
7. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002; 347: 1593-1603.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
9. Polyak K, Hahn CW. Roots and stems: stem cells in cancer. Nat Med 2005; 11: 296-300.
10. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer and cancer stem cells. Nature 2001; 414: 105-111.
11. Taniguchi H, Chiba T. Stem cells and cancer in the liver. Dis Markers 2008; 24: 223-229.
12. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
13. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 2007; 445: 106-110.
14. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-3988.
15. Collin AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951.
16. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65: 9328-9337.
17. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323.
18. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007; 104: 973-978.
19. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132: 2542-2556.
20. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153-166.
21. Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 2007; 67: 10831-10839.
22. Kurahashi N, Inoue M, Iwasaki M, Tanaka Y, Mizokami M, Tsugane S; JPHC Study Group. Vegetable, fruit and antioxidant nutrient consumption and subsequent risk of hepatocellular carcinoma: a prospective cohort study in Japan. Br J Cancer 2009; 100: 181-184.
23. Braga C, La Vecchia C, Negri E, Franceschi S. Attributable risks for hepatocellular carcinoma in northern Italy. Eur J Cancer 1997; 33: 629-634.
24. Lee TK, Poon RT, Guan XY, Ma S, Guan XY, Myers JN, et al. Lupeol suppresses cisplatin induced NFκB activation in HNSCC cells and inhibits local invasion and nodal metastasis in orthotopic nude mouse model of tongue squamous cell carcinoma. Cancer Res 2007; 67: 8800-8809.
25. Brown JJ, Parashar B, Moshage H, Tanaka KE, Engelhardt D, Rabbani E, et al. A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2-deficient mice. HEPATOLOGY 2000; 31: 173-181.
26. Saleem M, Afaq F, Adhami VM, Mukhtar H. Lupeol modulates NFκB and PI3/Akt pathways and inhibits skin cancer in CD-1 mice. Oncogene 2004; 23: 5203-5214.
27. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 2005; 7: 86-95.
28. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008; 27: 1749-1758.
29. Rountree CB, Ding W, He L, Stiles B. Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells 2009; 27: 290-299.
30. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activitiy in glioma tumor stem-like cells. Cell Stem Cell 2009; 4: 226-235.
31. Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, et al. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 2005; 117: 376-380.
32. Shi GM, Xu Y, Fan J, Zhou J, Yang XR, Qiu SJ, et al. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol 2008; 134: 1155-1163.
33. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
34. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signalling. PLoS Biol 2009; 7: e1000121.
35. Hettinger K, Vikhanskaya F, Poh MK, Lee MK, de Belle I, Zhang JT, et al. c-Jun promotes cellular survival by suppression of PTEN. Cell Death Differ 2007; 14: 218-229.
36. Han B, Dong Z, Liu Y, Chen Q, Hashimoto K, Zhang J-T. Regulation of constitutive expression of mouse PTEN by the 5'-untranslated region. Oncogene 2003; 22: 5325-5337.
37. Hu C, Li H, Zhu Z, Yin S, Hao X, Yao M, et al. Analysis of ABCG2 express and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signalling. Carcinogenesis 2008; 12: 2289-2297.
38. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009; 106: 16281-16286.